A Phase 1b/2 Dose Escalation Study of the Safety, Pharmacokinetics, and Efficacy of the Combination of TMB-365 and TMB-380 in HIV-1 Infected Individuals Suppressed With Combination Antiretroviral Therapy
Latest Information Update: 19 Mar 2025
At a glance
Most Recent Events
- 17 Mar 2025 According to a TaiMed Biologics media release, results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy was accepted for late-breaking presentation at CROI.
- 17 Mar 2025 Results presented in the TaiMed Biologics Media Release.
- 03 Feb 2025 Status changed from active, no longer recruiting to completed.